A computer simulation of employee vaccination to mitigate an influenza epidemic.

BACKGROUND Better understanding the possible effects of vaccinating employees is important and can help policymakers and businesses plan vaccine distribution and administration logistics, especially with the current H1N1 influenza vaccine in short supply. PURPOSE This article aims to determine the effects of varying vaccine coverage, compliance, administration rates, prioritization, and timing among employees during an influenza pandemic. METHODS As part of the H1N1 influenza planning efforts of the Models of Infectious Disease Agent Study network, an agent-based computer simulation model was developed for the Washington DC metropolitan region, encompassing five metropolitan statistical areas. Each simulation run involved introducing 100 infectious individuals to initiate a 1.3 reproductive-rate (R(0)) epidemic, consistent with H1N1 parameters to date. Another set of scenarios represented a R(0)=1.6 epidemic. RESULTS An unmitigated epidemic resulted in substantial productivity losses (a mean of $112.6 million for a serologic 15% attack rate and $193.8 million for a serologic 25% attack rate), even with the relatively low estimated mortality impact of H1N1. Although vaccinating Advisory Committee on Immunization Practices-defined priority groups resulted in the largest savings, vaccinating all remaining workers captured additional savings and, in fact, reduced healthcare workers' and critical infrastructure workers' chances of infection. Moreover, although employee vaccination compliance affected the epidemic, once 20% compliance was achieved, additional increases in compliance provided less incremental benefit. Even though a vast majority of the workplaces in the DC metropolitan region had fewer than 100 employees, focusing on vaccinating only those in larger firms (> or =100 employees) was just as effective in mitigating the epidemic as trying to vaccinate employees in all workplaces. CONCLUSIONS Timely vaccination of at least 20% of the large-company workforce can play an important role in epidemic mitigation.

[1]  C. Macken,et al.  Mitigation strategies for pandemic influenza in the United States. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[2]  E. Lyons,et al.  Pandemic Potential of a Strain of Influenza A (H1N1): Early Findings , 2009, Science.

[3]  T. Jefferson,et al.  Vaccines for preventing influenza in healthy adults. , 2000, The Cochrane database of systematic reviews.

[4]  D. Cummings,et al.  Strategies for containing an emerging influenza pandemic in Southeast Asia , 2005, Nature.

[5]  Frank A. Sloan,et al.  Valuing health care : costs, benefits, and effectiveness of pharmaceuticals and other medical technologies , 1995 .

[6]  A. Nizam,et al.  Containing pandemic influenza with antiviral agents. , 2004, American journal of epidemiology.

[7]  M. D. McKay,et al.  Creating synthetic baseline populations , 1996 .

[8]  N. Cox,et al.  Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[9]  T. Jefferson,et al.  Vaccines for preventing influenza in healthy children. , 2008, The Cochrane database of systematic reviews.

[10]  N. Cox,et al.  Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. , 2009 .

[11]  M Elizabeth Halloran,et al.  Population-wide benefits of routine vaccination of children against influenza. , 2005, Vaccine.

[12]  Laxminarayana Ganapathi,et al.  Synthesized Population Databases: A US Geospatial Database for Agent-Based Models. , 2009, Methods report.

[13]  Tom Jefferson,et al.  Vaccines for preventing influenza in the elderly. , 2010, The Cochrane database of systematic reviews.

[14]  M. Halloran,et al.  Estimating Influenza Vaccine Efficacy From Challenge and Community-based Study Data , 2008, American journal of epidemiology.

[15]  C. Wichems,et al.  Response after One Dose of a Monovalent Influenza A (H1N1) 2009 Vaccine — Preliminary Report , 2009 .

[16]  C. Macken,et al.  Modeling targeted layered containment of an influenza pandemic in the United States , 2008, Proceedings of the National Academy of Sciences.

[17]  Michael B Rothberg,et al.  Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. , 2005, The American journal of medicine.

[18]  D. Cummings,et al.  Strategies for mitigating an influenza pandemic , 2006, Nature.

[19]  A. Flahault,et al.  Estimating the impact of school closure on influenza transmission from Sentinel data , 2008, Nature.

[20]  Aravind Srinivasan,et al.  Modelling disease outbreaks in realistic urban social networks , 2004, Nature.

[21]  A. Schuchat Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. , 2009, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[22]  Troyen A. Brennan,et al.  The role of medical liability reform in federal health care reform. , 2009, The New England journal of medicine.

[23]  Gail E. Potter,et al.  The Transmissibility and Control of Pandemic Influenza A (H1N1) Virus , 2009, Science.

[24]  C. Wichems,et al.  Response to a monovalent 2009 influenza A (H1N1) vaccine. , 2009, The New England journal of medicine.

[25]  A. Nizam,et al.  Containing Pandemic Influenza at the Source , 2005, Science.